

Applicant: Graham P., Allaway et al.
Serial No: 09/852,238
Filed: May 9, 2001
Page 2

Remarks

In the October 22, 2001 Notice To Comply, the Examiner stated that the copy of the sequence listing in computer readable form has been submitted, but that the computer readable form (CRF) does not comply with the sequence requirements. The Notice states that applicant must provide a substitute CRF of the sequence listing and a statement that the content of the sequence listing information on the CRF is identical to the written listing and includes no new matter.

In response, applicants submit a substitute paper copy of the sequence listing attached hereto as **Exhibit B** in compliance with the requirements of 37 C.F.R. §1.824. In addition applicants submit herewith a substitute computer readable form (CFR) copy of the "Sequence Listing" as required by 37 C.F.R. §1.825(d). Further, applicants submit herewith as **Exhibit C** a statement in accordance with 37 C.F.R. §1.821(f), certifying that the substitute computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which was submitted as the "Sequence Listing" and contains no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invites the Examiner to telephone either of them at the number provided below.

Applicant: . Graham P. Allaway et al.
Serial No: 09/852,238
Filed : May 9, 2001

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,


JD

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

[Signature] 12-18-01
John P. White Date
Reg. No. 28,678
Spencer H. Schneider
Reg. No. 45,923

John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

EXHIBIT A

COPY OF PAPERS
ORIGINALLY FILED
 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/852,238	05/09/2001	Graham P. Allaway	51320-AB/JPW/SHS

CONFIRMATION NO. 4501

FORMALITIES LETTER



OC00000006946698

 John P. White
 Cooper & Dunham LLP
 1185 Avenue of the Americas
 New York, NY 10036

 received
 [Signature]

OCT 26 2001

Date Mailed: 10/22/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

B/S

 Customer Service Center
 Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

EXHIBIT B



51320-AB.ST25.txt

COPY OF PAPERS
ORIGINALLY FILED

#9

SEQUENCE LISTING

<110> Graham P. Allaway et al.

<120> USES OF A CHEMOKINE RECEPTOR FOR INHIBITING HIV-1 INFECTION

<130> 2048/51320-AB/JPW/SHS

<140> 09/852,238

<141> 2001-09-05

<160> 30

<170> PatentIn version 3.1

<210> 1

<211> 38

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 1

caaggctact tccctgattg gcagaactac acaccagg

38

<210> 2

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 2

agcaagccga gtcctgcgtc gagag

25

<210> 3

<211> 23

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 3
 gggactttcc gctggggact ttc
 23

<210> 4
 <211> 33
 <212> DNA
 <213> artificial sequence

<220>
 <223> primer

<400> 4
 cctgttcggg cgccactgct agagattttc cac
 33

<210> 5
 <211> 31
 <212> PRT
 <213> human

<400> 5

Met	Asp	Tyr	Gln	Val	Ser	Ser	Pro	Ile	Tyr	Asp	Ile	Asn	Tyr	Tyr	Thr
1				5					10					15	

Ser	Glu	Pro	Cys	Gln	Lys	Ile	Asn	Val	Lys	Gln	Ile	Ala	Ala	Arg
			20					25					30	

<210> 6
 <211> 15
 <212> PRT
 <213> human

<400> 6

His	Tyr	Ala	Ala	Ala	Gln	Trp	Asp	Phe	Gly	Asn	Thr	Met	Cys	Gln
1				5					10					15

<210> 7
 <211> 32
 <212> PRT

<213> human

<400> 7

Arg	Ser	Gln	Lys	Glu	Gly	Leu	His	Tyr	Thr	Cys	Ser	Ser	His	Phe	Pro
1				5					10					15	

Tyr	Ser	Gln	Tyr	Gln	Phe	Trp	Lys	Asn	Phe	Gln	Thr	Leu	Lys	Ile	Val
			20					25					30		

<210> 8

<211> 17

<212> PRT

<213> human

<400> 8

Gln	Glu	Phe	Phe	Gly	Leu	Asn	Asn	Cys	Ser	Ser	Ser	Asn	Arg	Leu	Asp
1				5					10					15	

Gln

<210> 9

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 9

aagcttg	ggag	aaccagc	gggt	taccatg	ggag	gggatc
						36

<210> 10

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 10
gtctgagtct gagtcaagct tggagaacca
30

<210> 11
<211> 41
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 11
ctcgagcatc tgtgtagct ggagtgaaaa cttgaagact c
41

<210> 12
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 12
gtctgagtct gagtccctga gcatctgtgt
30

<210> 13
<211> 32
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 13
aagcttcaga gagaagccgg gatggaaact cc
32

<210> 14
<211> 30
<212> DNA
<213> artificial sequence

<220>

<223> primer

<400> 14

gtctgagtct gagtcaagct tcagagagaa
30

<210> 15

<211> 32

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 15

ctcgagctga gtcagaaccc agcagagagt tc
32

<210> 16

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 16

gtctgagtct gaggcctcga gctgagtcag
30

<210> 17

<211> 32

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 17

aagcttcagt acatccacaa catgctgtcc ac
32

<210> 18
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 18
gtctgagtct gagtcaagct tcagtacatc
30

<210> 19
<211> 31
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 19
ctcgagcctc gttttataaaa ccagccgaga c
31

<210> 20
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 20
gtctgagtct gagtcctcga gcctcgtttt
30

<210> 21
<211> 29
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 21

aagcttcagg gagaagtgaa atgacaacc
29

<210> 22
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 22
gtctgagtct gagtcaagct tcagggagaa
30

<210> 23
<211> 33
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 23
ctcgagcaga cctaaaacac aatagagagt tcc
33

<210> 24
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 24
gtctgagtct gagtcctcga gcagacctaa
30

<210> 25
<211> 34
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 25
aagcttctgt agagttaaaa aatgaacccc acgg
34

<210> 26
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 26
gtctgagtct gagtcaagct tctgtagagt
30

<210> 27
<211> 34
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 27
ctcgagccat ttcatttttc tacaggacag catc
34

<210> 28
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 28
gtctgagtct gagtccctcga gccatttcac
30

<210> 29

<211> 39
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 29
gtctgagtct gagtcaagct taacaagatg gattatcaa
39

<210> 30
<211> 39
<212> DNA
<213> artificial sequence

<220>
<223> primer

<400> 30
gtctgagtct gagtctctga gtccgtgtcg caagccac
39

EXHIBIT C



COPY OF PAPERS
ORIGINALLY FILED

9

Dkt. No. 51320-AB/JPW/SHS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Graham P. Allaway, et al.
Serial No. : 09/852,238
Filed : May 9, 2001
For : USES OF A CHEMOKINE RECEPTOR FOR
INHIBITING HIV-1 INFECTION

1185 Avenue of the Americas
New York, New York 10036
December 18, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e) and submitted in connection with the above-identified application, has the same information as the pages attached hereto as **Exhibit B**, and entitled "Sequence Listing" and contains no new matter.

Respectfully submitted,

Spencer Schneider
Registration No. 45,923
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400